The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.

Abstract

BACKGROUND:

Both the 13- and 10-valent pneumococcal conjugate vaccines (PCV-13; PCV-10) are immunogenic and effective against vaccine-type pneumococcal disease when given to young children. However, limited data are available regarding the interchangeability of these 2 vaccines.

METHODS:

UK children (n = 178) who had previously been vaccinated with PCV-13 at 2 and 4 months were randomized to receive either a PCV-13 or a PCV-10 booster at 12 months of age. PCV-13 vaccine-type antipolysaccharide serum immunoglobulin G (IgG) concentrations and opsonophagocytic assay titers were measured before and at 1 and 12 months following vaccination. The primary objective was to assess noninferiority of PCV-10 compared with PCV-13.

RESULTS:

For 8 of the PCV-10 serotypes at least 97% of participants in both groups had IgG concentrations ≥0.35 µg/mL at 1 month after vaccination; inferior responses were seen for serotypes 5 and 9V following the PCV-10 compared with the PCV-13 booster. Post booster geometric mean IgG concentrations and opsonophagocytic assay titers were significantly superior for most serotypes in PCV-13 compared with PCV-10 recipients, whereas similar or inferior responses were seen for serotypes 4, 18C, and 19F. Although some increase in antibody was seen in PCV-10 recipients against the serotypes 6A and 19A (serotypes that cross-react with 6B and 19F in PCV-10, respectively) at 1-month post booster, these responses were significantly lower than in the PCV-13 group.

CONCLUSIONS:

In PCV-13 primed infants, a PCV-10 booster is generally less immunogenic than a PCV-13 booster. For the 3 serotypes in PCV-10 with higher antigen content and/or conjugation to diphtheria or tetanus toxoid carrier proteins, higher or similar booster responses were seen in PCV-10 recipients. Although these findings suggest that responses are generally better with a PCV-13 booster among PCV-13 primed children, the clinical significance of these differences in immunogenicity is unclear.

• Authors: Johannes Trück, Sena Jawad, David Goldblatt, Lucy Roalfe, Matthew D Snape, Merryn Voysey, Andrew J Pollard
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 35 Issue 7 Pg. 787-93 (07 2016) ISSN: 1532-0987 [Electronic] United States
• PMID: 27088583 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• 10-valent pneumococcal conjugate vaccine
• 13-valent pneumococcal vaccine
• Antibodies, Bacterial
• Immunoglobulin G
• Pneumococcal Vaccines
• Vaccines, Conjugate

Topics

• Antibodies, Bacterial (blood, immunology)
• Antibody Formation (drug effects, immunology)
• Diphtheria (immunology, prevention & control)
• Female
• Humans
• Immunization, Secondary (methods)
• Immunoglobulin G (blood)
• Infant
• Male
• Pneumococcal Infections (prevention & control)
• Pneumococcal Vaccines (administration & dosage, immunology)
• United Kingdom
• Vaccines, Conjugate (administration & dosage, immunology)